EUVIMEDEUVIMED entdecken
Crossref

Influenta produselor finale de glicare avansata (AGEs) la pacienții cu tuberculoza pulmonara si diabet zaharat

Marina REABÎȘEVA, Anatolie VISNEVSCH, Doina RUSU

Management in Health · 30.06.2026 · 30 (2) · 10-14

DOI: 10.5233/3ctcqx72 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Management in Health, online erschienen am 30.06.2026. Verfasst von Marina REABÎȘEVA und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION. The coexistence of diabetes mellitus (DM) andpulmonary tuberculosis (TB) represents a major global public healthchallenge, with diabetes being recognized as an important risk factor for thedevelopment and progression of TB. Chronic hyperglycemia promotes theformation and accumulation of advanced glycation end products (AGE),which contribute to oxidative stress, persistent inflammation, and immunedysfunction. In patients with TB-DM comorbidity, elevated AGE levels mayimpair innate and adaptive immune responses by reducing phagocyticactivity, altering macrophage function, and delaying antigen presentation,thereby favoring the persistence and severity of Mycobacterium tuberculosisinfection.OBJECTIVE. To evaluate the influence of advanced glycation endproducts (AGE) in patients with pulmonary tuberculosis and diabetes mellitusand to determine their role in the inflammatory and immune responseassociated with TB-DM comorbidity.MATERIAL AND METHODS. The prospective observational study wasconducted at the “Chiril Draganiuc” Institute of Pneumology during theperiod 2019–2024 and included 118 patients. The study population wasdivided into two subgroups: group L1, consisting of 59 patients withpulmonary tuberculosis and diabetes mellitus, and group L2, comprising 59patients with pulmonary tuberculosis without diabetes mellitus. Allparticipants were assessed before and after in-hospital treatment. Thediagnosis of pulmonary tuberculosis was confirmed by acid-fast bacilli (AFB)smear microscopy and the molecular-genetic method Xpert MTB/RIF. Inorder to evaluate the influence of advanced glycation end products (AGEs) inTB-DM comorbidity, serum AGE levels, biomarkers of systemic inflammationlike Ceruloplasmin and C-reactive protein were determined andcomparatively analyzed between the study groups.RESULTS. In the study, we demonstrated importance of AGEs andsystemic inflammatory markers Ceruloplasmin and C-reactive protein (CRP)showed distinct dynamics during treatment. In the TB-DM group,ceruloplasmin exhibited a more moderate increase of 19.3%, compared to30.8% in group 1. Diabetes mellitus was also associated with a lower overallrise in serum AGE levels, reaching 153% by the end of therapy. Regardingbacteriological outcomes, the proportion of patients with negative AFBresults decreased 2.3-fold in the study group during treatment, whereas ingroup 1 the reduction was more pronounced, reaching 5.4-fold, with a declinefrom 62.7% to 27.1%. A similar trend was observed for Xpert MTB/RIF, witha decrease in the number of negative patients in both groups throughouttherapy.Overall, the coexistence of these two conditions is characterized by amore pronounced attenuation of the immune–inflammatory response duringanti-tuberculosis treatment.CONCLUSION. Overall, these findings indicate that AGEs,ceruloplasmin, and C-reactive protein collectively represent valuablebiomarkers reflecting the complex interaction between oxidative stress,inflammation, and immune dysfunction in pulmonary tuberculosis associatedwith type II diabetes mellitus, and may serve as useful indicators for diseaseseverity, progression, and therapeutic response.

Zitieren

APA

REABÎȘEVA, M., VISNEVSCH, A., & RUSU, D. (2026). Influenta produselor finale de glicare avansata (AGEs) la pacienții cu tuberculoza pulmonara si diabet zaharat. Management in Health, 30(2), 10-14. https://doi.org/10.5233/3ctcqx72

Vancouver

REABÎȘEVA M, VISNEVSCH A, RUSU D. Influenta produselor finale de glicare avansata (AGEs) la pacienții cu tuberculoza pulmonara si diabet zaharat. Management in Health. 2026;30(2):10-14. doi:10.5233/3ctcqx72

BibTeX
@article{REABEVA2026,
  author = {REABÎȘEVA, Marina and VISNEVSCH, Anatolie and RUSU, Doina},
  title = {Influenta produselor finale de glicare avansata (AGEs) la pacienții cu tuberculoza pulmonara si diabet zaharat},
  journal = {Management in Health},
  year = {2026},
  volume = {30},
  number = {2},
  pages = {10--14},
  doi = {10.5233/3ctcqx72}
}
Kostenlos starten →